{"gene":"TERF2","run_date":"2026-06-10T10:51:54","timeline":{"discoveries":[{"year":2022,"finding":"TERF2 binds directly to the non-histone chromatin-associated protein HMGB1, and this interaction controls HMGB1 nuclear/cytoplasmic localization. Silencing of TERF2 promotes cytosolic translocation of HMGB1 and stimulates autophagy; overexpression of wild-type TERF2 (but not a mutant unable to bind HMGB1) suppresses HMGB1 cytoplasmic translocation and inhibits autophagy. Genetic depletion of HMGB1 or pharmacological inhibition of its cytosolic translocation abolishes the pro-autophagic effect of TERF2 silencing, placing TERF2 upstream of HMGB1 in autophagic regulation.","method":"Co-immunoprecipitation, proximity ligation assay, immunofluorescence, overexpression of wild-type vs. binding-deficient TERF2 mutant, HMGB1 knockdown/chemical inhibitor (inflachromene), redox assays (DCFDA, DHE, GSH/GSSG), GFP-LC3 autophagy reporter","journal":"Autophagy","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal biochemical interaction validated by Co-IP and PLA, functional rescue by binding-deficient mutant, and genetic epistasis via HMGB1 depletion; multiple orthogonal methods in a single rigorous study","pmids":["36310382"],"is_preprint":false},{"year":2017,"finding":"Selective inactivation of Terf2 in mouse neural progenitors induces telomere dysfunction leading to apoptosis and complete loss of brain structure. ATM and TP53, but not ATR, are required for this neural cell loss. p53 deficiency leads to formation of multinucleated giant neural cells whose appearance is suppressed by Lig4 (NHEJ factor) deficiency, indicating that unrepaired DSBs drive their formation.","method":"Conditional mouse Terf2 knockout in neural progenitors; genetic crosses with Atm, Atr, Trp53, and Lig4 knockout mice; histological and immunofluorescence analysis of brain development","journal":"Histochemistry and cell biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional knockout with multiple genetic epistasis crosses (Atm, Atr, p53, Lig4), rigorous developmental phenotype readout","pmids":["28620865"],"is_preprint":false},{"year":2006,"finding":"TERF2 forms a complex with the nucleotide excision repair endonuclease XPF. This TERF2-XPF complex functions at non-telomeric sites of DNA damage, acting prior to initiation of the ATM signaling cascade. Overexpression of TERF2 produces cellular hypersensitivity to UV radiation and DNA crosslinking agents; these abnormal responses are not observed in an XPF-deficient background, demonstrating that the phenotype is XPF-dependent.","method":"Review/commentary synthesizing two experimental papers; overexpression of TERF2 in XPF-deficient vs. XPF-proficient cells; UV/crosslinker sensitivity assays; mouse genetic models","journal":"DNA repair","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis in XPF-null background with defined phenotypic readout; evidence is from original papers summarized in a review commentary, single-lab replication context","pmids":["16762604"],"is_preprint":false},{"year":2005,"finding":"In muntjac cell lines, TRF2 (TERF2) localizes to telomeres in vivo; deletion of its DNA-binding domain abolishes this telomeric localization, demonstrating that the DNA-binding domain is required for proper chromosomal-end targeting of TERF2.","method":"TRF2-GFP fusion live-cell imaging and immunostaining in muntjac fibroblast cell lines; deletion mutant analysis","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — direct localization experiment with functional domain deletion in a mammalian-ortholog cell line; single lab, single method","pmids":["15878333"],"is_preprint":false},{"year":2024,"finding":"The TERF2::PDGFRB chromosomal fusion gene drives IL-3-independent proliferation of Ba/F3 cells through activation of p-PDGFRB and p-STAT5 signaling pathways, reduces apoptosis, and induces tumorigenesis in mouse cell-derived graft models; these effects are sensitive to the tyrosine kinase inhibitor imatinib.","method":"Ba/F3 cell expression of TERF2::PDGFRB fusion; IL-3-independent proliferation assay; Western blot for p-PDGFRB and p-STAT5; apoptosis assays; mouse xenograft/CDG models; imatinib treatment","journal":"Journal of cellular and molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional cell-based and in vivo models with defined signaling pathway (PDGFRB/STAT5) and drug sensitivity; single lab, multiple orthogonal methods","pmids":["38323741"],"is_preprint":false},{"year":2024,"finding":"miR-29b-1-5p directly targets the TERF2 3'UTR (validated by dual luciferase assay), negatively regulating TERF2 expression. TERF2 knockdown partially restores the pro-injury effect that miR-29b-1-5p inhibition suppresses in LPS-stimulated cardiomyocytes, placing TERF2 downstream of miR-29b-1-5p in sepsis-induced myocardial injury.","method":"TargetScan prediction, dual luciferase reporter assay, miR-29b-1-5p antagomir transduction, TERF2 knockdown in HL-1 cardiomyocytes, LPS/CLP mouse sepsis model, Western blot, flow cytometry","journal":"Acta biochimica et biophysica Sinica","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — dual luciferase validation of direct miRNA-target interaction plus genetic epistasis via TERF2 knockdown rescue experiment; single lab","pmids":["38414350"],"is_preprint":false},{"year":2024,"finding":"TOP3A stabilizes TERF2 protein at telomeres in ALT (alternative lengthening of telomeres) cancer cells but not in telomerase-positive cancer cells. Induction of TOP3A-DNA-protein crosslinks in ALT cells destabilizes TERF2 at telomeres, indicating TOP3A activity is required to maintain TERF2 association with ALT telomeres.","method":"ChIP/telomere enrichment assays comparing ALT vs. telomerase-positive cell lines; TOP3A depletion and TOP3A-DPC induction; Western blot and immunofluorescence for TERF2 stability","journal":"bioRxiv","confidence":"Low","confidence_rationale":"Tier 3 / Weak — preprint, single lab, biochemical enrichment assays without full mechanistic reconstitution; novel context-specific finding","pmids":["bio_10.1101_2024.11.18.624152"],"is_preprint":true},{"year":2025,"finding":"In cardiomyocytes from failing human hearts (idiopathic dilated cardiomyopathy and ischemic heart disease), TERF2 association with telomeres is markedly reduced compared to non-failing hearts. This TERF2 de-protection correlates with telomere 3'-overhang attrition, increased γH2AX at telomeres, and persistent ATM-mediated DNA damage response (TIF formation).","method":"Telomere ChIP and chromatin fractionation from human left ventricular tissue; γH2AX immunostaining; TIF assays; telomere overhang length measurement; comparison of IDC, IHD, and non-failing heart samples","journal":"bioRxiv","confidence":"Low","confidence_rationale":"Tier 3 / Weak — preprint, observational/correlative biochemical measurements in human tissue without functional manipulation of TERF2","pmids":["bio_10.1101_2025.08.12.669993"],"is_preprint":true}],"current_model":"TERF2 (TRF2) is a telomeric double-strand DNA-binding protein whose DNA-binding domain is required for telomeric localization; it protects chromosome ends by suppressing ATM-dependent DNA damage signaling (acting via ATM and TP53 in neural cells), forms a complex with XPF to participate in non-telomeric DNA damage responses, interacts directly with HMGB1 to restrict its cytoplasmic translocation and thereby suppress autophagy, and in ALT cancer cells is stabilized at telomeres by TOP3A activity."},"narrative":{"mechanistic_narrative":"TERF2 (TRF2) is a telomeric double-strand DNA-binding protein that protects chromosome ends and governs the DNA damage response, with its DNA-binding domain required for proper targeting to telomeres [PMID:15878333]. At chromosome ends, loss of TERF2 triggers telomere dysfunction that activates an ATM- and TP53-dependent, ATR-independent apoptotic program; in neural progenitors this drives catastrophic cell loss, and unrepaired double-strand breaks processed by NHEJ (Lig4) underlie the multinucleated cells that arise when p53 is absent [PMID:28620865]. Beyond telomeres, TERF2 forms a complex with the nucleotide excision repair endonuclease XPF that acts at non-telomeric damage sites upstream of ATM signaling, such that TERF2 overexpression sensitizes cells to UV and crosslinking agents in an XPF-dependent manner [PMID:16762604]. TERF2 also exerts a non-telomeric regulatory role by binding directly to HMGB1 and restricting its cytoplasmic translocation; this interaction suppresses autophagy, as TERF2 silencing drives HMGB1 to the cytosol and stimulates autophagy while a binding-deficient mutant fails to suppress it [PMID:36310382].","teleology":[{"year":2005,"claim":"Established that TERF2's telomeric localization is an intrinsic property of its DNA-binding domain, defining how the protein finds chromosome ends.","evidence":"TRF2-GFP fusion imaging and DNA-binding-domain deletion mutants in muntjac fibroblast cell lines","pmids":["15878333"],"confidence":"Medium","gaps":["Single lab and single ortholog cell line","Does not address what stabilizes TERF2 once bound or which cofactors are required","No structural detail of the DNA-binding interface"]},{"year":2006,"claim":"Extended TERF2 function beyond telomeres by showing it partners with XPF to act at non-telomeric DNA damage sites prior to ATM signaling.","evidence":"TERF2 overexpression in XPF-deficient vs. XPF-proficient cells with UV/crosslinker sensitivity assays, synthesized in a review commentary","pmids":["16762604"],"confidence":"Medium","gaps":["Evidence summarized from original papers in a review context","Molecular nature of the TERF2-XPF complex and its substrate are not defined","Physiological relevance of the gain-of-function hypersensitivity is unclear"]},{"year":2017,"claim":"Defined the genetic pathway of TERF2 loss in vivo, showing telomere dysfunction signals through ATM and TP53 (not ATR) to drive apoptosis and that NHEJ underlies aberrant cell formation.","evidence":"Conditional Terf2 knockout in mouse neural progenitors crossed with Atm, Atr, Trp53, and Lig4 knockouts, with developmental histology","pmids":["28620865"],"confidence":"High","gaps":["Restricted to the neural progenitor context","Does not resolve the molecular step linking telomere deprotection to ATM activation","Role of TERF2 partners in this signaling is not addressed"]},{"year":2022,"claim":"Uncovered a non-telomeric role for TERF2 as a direct binding partner that sequesters HMGB1 in the nucleus to restrain autophagy.","evidence":"Co-IP, PLA, wild-type vs. binding-deficient TERF2 mutant rescue, HMGB1 knockdown/inhibitor epistasis, and GFP-LC3 autophagy reporter","pmids":["36310382"],"confidence":"High","gaps":["Whether HMGB1 binding occurs at telomeres or elsewhere is not localized","How TERF2's telomeric and autophagy-regulatory functions are coordinated is unknown","In vivo relevance of the autophagy axis is not established"]},{"year":2024,"claim":"Positioned TERF2 within regulatory and oncogenic networks: as a target of miR-29b-1-5p in myocardial injury and, when fused to PDGFRB, as a driver of kinase-dependent proliferation.","evidence":"Dual luciferase 3'UTR validation with TERF2-knockdown rescue in cardiomyocytes; Ba/F3 expression of TERF2::PDGFRB fusion with STAT5 signaling readouts and imatinib sensitivity","pmids":["38414350","38323741"],"confidence":"Medium","gaps":["miR-29b axis is correlative for endogenous TERF2 protein function","The fusion's oncogenic activity reflects PDGFRB kinase rather than native TERF2 function","Single-lab studies in defined model systems"]},{"year":2024,"claim":"Began to address how TERF2 is retained at telomeres in ALT cancer cells, implicating TOP3A activity in its stabilization.","evidence":"Telomere enrichment/ChIP comparing ALT vs. telomerase-positive cells with TOP3A depletion and DPC induction (preprint)","pmids":["bio_10.1101_2024.11.18.624152"],"confidence":"Low","gaps":["Preprint; lacks full mechanistic reconstitution","Mechanism by which TOP3A stabilizes TERF2 is undefined","Generalizability beyond the ALT cell context is untested"]},{"year":2025,"claim":"Correlated TERF2 telomere de-protection with disease, linking reduced telomeric TERF2 to telomere damage signaling in failing human hearts.","evidence":"Telomere ChIP, γH2AX/TIF assays, and overhang measurements in failing vs. non-failing human left ventricular tissue (preprint)","pmids":["bio_10.1101_2025.08.12.669993"],"confidence":"Low","gaps":["Preprint; observational and correlative without TERF2 manipulation","Causality between TERF2 loss and heart failure is not established","Mechanism of TERF2 loss from telomeres in failing hearts is unknown"]},{"year":null,"claim":"How TERF2 coordinates its telomere-protective DNA-binding role with its non-telomeric XPF and HMGB1 functions, and what governs its stability at telomeres in different cellular contexts, remains unresolved.","evidence":"","pmids":[],"confidence":"Low","gaps":["No structural model integrating DNA binding with partner interactions","Mechanism of TERF2 stabilization/loss at telomeres across cell types undefined","Direct causal link between TERF2 de-protection and human disease not demonstrated"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[3]}],"localization":[{"term_id":"GO:0000228","term_label":"nuclear chromosome","supporting_discovery_ids":[3,1]}],"pathway":[{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[2,1]},{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[0]}],"complexes":[],"partners":["HMGB1","XPF"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q15554","full_name":"Telomeric repeat-binding factor 2","aliases":["TTAGGG repeat-binding factor 2","Telomeric DNA-binding protein"],"length_aa":542,"mass_kda":59.6,"function":"Binds the telomeric double-stranded 5'-TTAGGG-3' repeat and plays a central role in telomere maintenance and protection against end-to-end fusion of chromosomes (PubMed:15608617, PubMed:16166375, PubMed:20655466, PubMed:28216226, PubMed:31595153, PubMed:9326950, PubMed:9326951, PubMed:9476899). In addition to its telomeric DNA-binding role, required to recruit a number of factors and enzymes required for telomere protection, including the shelterin complex, TERF2IP/RAP1 and DCLRE1B/Apollo (PubMed:16166375, PubMed:20655466). Component of the shelterin complex (telosome) that is involved in the regulation of telomere length and protection (PubMed:16166375). Shelterin associates with arrays of double-stranded 5'-TTAGGG-3' repeats added by telomerase and protects chromosome ends; without its protective activity, telomeres are no longer hidden from the DNA damage surveillance and chromosome ends are inappropriately processed by DNA repair pathways (PubMed:16166375). Together with DCLRE1B/Apollo, plays a key role in telomeric loop (T loop) formation by generating 3' single-stranded overhang at the leading end telomeres: T loops have been proposed to protect chromosome ends from degradation and repair (PubMed:20655466). Required both to recruit DCLRE1B/Apollo to telomeres and activate the exonuclease activity of DCLRE1B/Apollo (PubMed:20655466, PubMed:28216226). Preferentially binds to positive supercoiled DNA (PubMed:15608617, PubMed:20655466). Together with DCLRE1B/Apollo, required to control the amount of DNA topoisomerase (TOP1, TOP2A and TOP2B) needed for telomere replication during fork passage and prevent aberrant telomere topology (PubMed:20655466). Recruits TERF2IP/RAP1 to telomeres, thereby participating in to repressing homology-directed repair (HDR), which can affect telomere length (By similarity)","subcellular_location":"Nucleus; Chromosome, telomere","url":"https://www.uniprot.org/uniprotkb/Q15554/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":true,"resolved_as":"","url":"https://depmap.org/portal/gene/TERF2","classification":"Common Essential","n_dependent_lines":1046,"n_total_lines":1090,"dependency_fraction":0.9596330275229358},"opencell":{"profiled":true,"resolved_as":"","ensg_id":"ENSG00000132604","cell_line_id":"CID001730","localizations":[{"compartment":"nuclear_punctae","grade":3},{"compartment":"nucleoplasm","grade":2}],"interactors":[{"gene":"TERF2IP","stoichiometry":10.0},{"gene":"CPSF6","stoichiometry":0.2},{"gene":"HIST2H2BE","stoichiometry":0.2},{"gene":"POT1","stoichiometry":0.2},{"gene":"SNRPA","stoichiometry":0.2},{"gene":"SNRPF","stoichiometry":0.2},{"gene":"SSRP1","stoichiometry":0.2},{"gene":"SUPT5H","stoichiometry":0.2},{"gene":"PCM1","stoichiometry":0.2},{"gene":"TPP2","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/target/CID001730","total_profiled":1310},"omim":[{"mim_id":"620133","title":"DYSKERATOSIS CONGENITA, AUTOSOMAL RECESSIVE 8; DKCB8","url":"https://www.omim.org/entry/620133"},{"mim_id":"618576","title":"ZINC FINGER- AND BTB DOMAIN-CONTAINING PROTEIN 10; ZBTB10","url":"https://www.omim.org/entry/618576"},{"mim_id":"617962","title":"ZINC FINGER PROTEIN 827; ZNF827","url":"https://www.omim.org/entry/617962"},{"mim_id":"615823","title":"SLX1 HOMOLOG B, STRUCTURE-SPECIFIC ENDONUCLEASE SUBUNIT; SLX1B","url":"https://www.omim.org/entry/615823"},{"mim_id":"615822","title":"SLX1 HOMOLOG A, STRUCTURE-SPECIFIC ENDONUCLEASE SUBUNIT; SLX1A","url":"https://www.omim.org/entry/615822"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Nuclear bodies","reliability":"Supported"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/TERF2"},"hgnc":{"alias_symbol":["TRF2"],"prev_symbol":["TRBF2"]},"alphafold":{"accession":"Q15554","domains":[{"cath_id":"1.25.40.210","chopping":"88-278","consensus_level":"high","plddt":93.8276,"start":88,"end":278},{"cath_id":"1.10.10.60","chopping":"495-540","consensus_level":"high","plddt":91.005,"start":495,"end":540}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q15554","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q15554-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q15554-F1-predicted_aligned_error_v6.png","plddt_mean":68.0},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TERF2","jax_strain_url":"https://www.jax.org/strain/search?query=TERF2"},"sequence":{"accession":"Q15554","fasta_url":"https://rest.uniprot.org/uniprotkb/Q15554.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q15554/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q15554"}},"corpus_meta":[{"pmid":"20135196","id":"PMC_20135196","title":"Enhanced tolerance to freezing in tobacco and tomato overexpressing transcription factor TERF2/LeERF2 is modulated by ethylene biosynthesis.","date":"2010","source":"Plant molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/20135196","citation_count":149,"is_preprint":false},{"pmid":"21136294","id":"PMC_21136294","title":"Overexpression of ethylene response factor TERF2 confers cold tolerance in rice seedlings.","date":"2010","source":"Transgenic research","url":"https://pubmed.ncbi.nlm.nih.gov/21136294","citation_count":54,"is_preprint":false},{"pmid":"36310382","id":"PMC_36310382","title":"The telomeric protein TERF2/TRF2 impairs HMGB1-driven autophagy.","date":"2022","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/36310382","citation_count":25,"is_preprint":false},{"pmid":"34482039","id":"PMC_34482039","title":"Morphine treatment is associated with diminished telomere length together with down-regulated TERT and TERF2 mRNA levels.","date":"2021","source":"Drug and alcohol dependence","url":"https://pubmed.ncbi.nlm.nih.gov/34482039","citation_count":14,"is_preprint":false},{"pmid":"29043869","id":"PMC_29043869","title":"Identifying the biomarker potential of telomerase activity and shelterin complex molecule, telomeric repeat binding factor 2 (TERF2), in multiple myeloma.","date":"2017","source":"Leukemia & lymphoma","url":"https://pubmed.ncbi.nlm.nih.gov/29043869","citation_count":13,"is_preprint":false},{"pmid":"25536555","id":"PMC_25536555","title":"TERF1 and TERF2 downregulate telomere length in cognitive deficit at the late period after low-dose exposure.","date":"2014","source":"Problemy radiatsiinoi medytsyny ta radiobiolohii","url":"https://pubmed.ncbi.nlm.nih.gov/25536555","citation_count":9,"is_preprint":false},{"pmid":"38323741","id":"PMC_38323741","title":"The novel TERF2::PDGFRB fusion gene enhances tumorigenesis via PDGFRB/STAT5 signalling pathways and sensitivity to TKI in ph-like ALL.","date":"2024","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38323741","citation_count":5,"is_preprint":false},{"pmid":"15878333","id":"PMC_15878333","title":"Characterization of the telomere complex, TERF1 and TERF2 genes in muntjac species with fusion karyotypes.","date":"2005","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/15878333","citation_count":5,"is_preprint":false},{"pmid":"28620865","id":"PMC_28620865","title":"Involvement of Atm and Trp53 in neural cell loss due to Terf2 inactivation during mouse brain development.","date":"2017","source":"Histochemistry and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/28620865","citation_count":5,"is_preprint":false},{"pmid":"16762604","id":"PMC_16762604","title":"TERF2-XPF: caught in the middle; beginnings from the end.","date":"2006","source":"DNA repair","url":"https://pubmed.ncbi.nlm.nih.gov/16762604","citation_count":4,"is_preprint":false},{"pmid":"38414350","id":"PMC_38414350","title":"miR-29b-1-5p exacerbates myocardial injury induced by sepsis in a mouse model by targeting TERF2.","date":"2024","source":"Acta biochimica et biophysica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/38414350","citation_count":3,"is_preprint":false},{"pmid":"39328506","id":"PMC_39328506","title":"Expression and functional analyses of TERF2 in esophageal carcinoma.","date":"2024","source":"Heliyon","url":"https://pubmed.ncbi.nlm.nih.gov/39328506","citation_count":2,"is_preprint":false},{"pmid":"39994081","id":"PMC_39994081","title":"Pan‑cancer analysis of the oncogenic role of telomeric repeat binding factor 2 (TERF2) in human tumors and in vitro validation in gastric cancer by TERF2 knockdown.","date":"2025","source":"Discover oncology","url":"https://pubmed.ncbi.nlm.nih.gov/39994081","citation_count":1,"is_preprint":false},{"pmid":"40974379","id":"PMC_40974379","title":"Imatinib and blinatumomab successfully rescued a pediatric B-ALL patient with TERF2::PDGFRB fusion resistant to dasatinib and chemotherapy.","date":"2025","source":"Annals of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/40974379","citation_count":1,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.08.12.669993","title":"Telomere 3’-overhang attrition and persistent telomeric DNA damage response in failing human hearts","date":"2025-08-17","source":"bioRxiv","url":"https://doi.org/10.1101/2025.08.12.669993","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.11.18.624152","title":"Topoisomerase 3α (TOP3A) Dependent Alternative Lengthening of Telomeres (ALT)","date":"2024-11-19","source":"bioRxiv","url":"https://doi.org/10.1101/2024.11.18.624152","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":10990,"output_tokens":2490,"usd":0.03516,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":9580,"output_tokens":2791,"usd":0.058838,"stage2_stop_reason":"end_turn"},"total_usd":0.093998,"stage1_batch_id":"msgbatch_017qqVz33Ga63SCDwzb35XPb","stage2_batch_id":"msgbatch_01Scr2Ei9x4HJMiRGxwrmvLK","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2022,\n      \"finding\": \"TERF2 binds directly to the non-histone chromatin-associated protein HMGB1, and this interaction controls HMGB1 nuclear/cytoplasmic localization. Silencing of TERF2 promotes cytosolic translocation of HMGB1 and stimulates autophagy; overexpression of wild-type TERF2 (but not a mutant unable to bind HMGB1) suppresses HMGB1 cytoplasmic translocation and inhibits autophagy. Genetic depletion of HMGB1 or pharmacological inhibition of its cytosolic translocation abolishes the pro-autophagic effect of TERF2 silencing, placing TERF2 upstream of HMGB1 in autophagic regulation.\",\n      \"method\": \"Co-immunoprecipitation, proximity ligation assay, immunofluorescence, overexpression of wild-type vs. binding-deficient TERF2 mutant, HMGB1 knockdown/chemical inhibitor (inflachromene), redox assays (DCFDA, DHE, GSH/GSSG), GFP-LC3 autophagy reporter\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal biochemical interaction validated by Co-IP and PLA, functional rescue by binding-deficient mutant, and genetic epistasis via HMGB1 depletion; multiple orthogonal methods in a single rigorous study\",\n      \"pmids\": [\"36310382\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Selective inactivation of Terf2 in mouse neural progenitors induces telomere dysfunction leading to apoptosis and complete loss of brain structure. ATM and TP53, but not ATR, are required for this neural cell loss. p53 deficiency leads to formation of multinucleated giant neural cells whose appearance is suppressed by Lig4 (NHEJ factor) deficiency, indicating that unrepaired DSBs drive their formation.\",\n      \"method\": \"Conditional mouse Terf2 knockout in neural progenitors; genetic crosses with Atm, Atr, Trp53, and Lig4 knockout mice; histological and immunofluorescence analysis of brain development\",\n      \"journal\": \"Histochemistry and cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional knockout with multiple genetic epistasis crosses (Atm, Atr, p53, Lig4), rigorous developmental phenotype readout\",\n      \"pmids\": [\"28620865\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"TERF2 forms a complex with the nucleotide excision repair endonuclease XPF. This TERF2-XPF complex functions at non-telomeric sites of DNA damage, acting prior to initiation of the ATM signaling cascade. Overexpression of TERF2 produces cellular hypersensitivity to UV radiation and DNA crosslinking agents; these abnormal responses are not observed in an XPF-deficient background, demonstrating that the phenotype is XPF-dependent.\",\n      \"method\": \"Review/commentary synthesizing two experimental papers; overexpression of TERF2 in XPF-deficient vs. XPF-proficient cells; UV/crosslinker sensitivity assays; mouse genetic models\",\n      \"journal\": \"DNA repair\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis in XPF-null background with defined phenotypic readout; evidence is from original papers summarized in a review commentary, single-lab replication context\",\n      \"pmids\": [\"16762604\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"In muntjac cell lines, TRF2 (TERF2) localizes to telomeres in vivo; deletion of its DNA-binding domain abolishes this telomeric localization, demonstrating that the DNA-binding domain is required for proper chromosomal-end targeting of TERF2.\",\n      \"method\": \"TRF2-GFP fusion live-cell imaging and immunostaining in muntjac fibroblast cell lines; deletion mutant analysis\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — direct localization experiment with functional domain deletion in a mammalian-ortholog cell line; single lab, single method\",\n      \"pmids\": [\"15878333\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"The TERF2::PDGFRB chromosomal fusion gene drives IL-3-independent proliferation of Ba/F3 cells through activation of p-PDGFRB and p-STAT5 signaling pathways, reduces apoptosis, and induces tumorigenesis in mouse cell-derived graft models; these effects are sensitive to the tyrosine kinase inhibitor imatinib.\",\n      \"method\": \"Ba/F3 cell expression of TERF2::PDGFRB fusion; IL-3-independent proliferation assay; Western blot for p-PDGFRB and p-STAT5; apoptosis assays; mouse xenograft/CDG models; imatinib treatment\",\n      \"journal\": \"Journal of cellular and molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional cell-based and in vivo models with defined signaling pathway (PDGFRB/STAT5) and drug sensitivity; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"38323741\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"miR-29b-1-5p directly targets the TERF2 3'UTR (validated by dual luciferase assay), negatively regulating TERF2 expression. TERF2 knockdown partially restores the pro-injury effect that miR-29b-1-5p inhibition suppresses in LPS-stimulated cardiomyocytes, placing TERF2 downstream of miR-29b-1-5p in sepsis-induced myocardial injury.\",\n      \"method\": \"TargetScan prediction, dual luciferase reporter assay, miR-29b-1-5p antagomir transduction, TERF2 knockdown in HL-1 cardiomyocytes, LPS/CLP mouse sepsis model, Western blot, flow cytometry\",\n      \"journal\": \"Acta biochimica et biophysica Sinica\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — dual luciferase validation of direct miRNA-target interaction plus genetic epistasis via TERF2 knockdown rescue experiment; single lab\",\n      \"pmids\": [\"38414350\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"TOP3A stabilizes TERF2 protein at telomeres in ALT (alternative lengthening of telomeres) cancer cells but not in telomerase-positive cancer cells. Induction of TOP3A-DNA-protein crosslinks in ALT cells destabilizes TERF2 at telomeres, indicating TOP3A activity is required to maintain TERF2 association with ALT telomeres.\",\n      \"method\": \"ChIP/telomere enrichment assays comparing ALT vs. telomerase-positive cell lines; TOP3A depletion and TOP3A-DPC induction; Western blot and immunofluorescence for TERF2 stability\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — preprint, single lab, biochemical enrichment assays without full mechanistic reconstitution; novel context-specific finding\",\n      \"pmids\": [\"bio_10.1101_2024.11.18.624152\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"In cardiomyocytes from failing human hearts (idiopathic dilated cardiomyopathy and ischemic heart disease), TERF2 association with telomeres is markedly reduced compared to non-failing hearts. This TERF2 de-protection correlates with telomere 3'-overhang attrition, increased γH2AX at telomeres, and persistent ATM-mediated DNA damage response (TIF formation).\",\n      \"method\": \"Telomere ChIP and chromatin fractionation from human left ventricular tissue; γH2AX immunostaining; TIF assays; telomere overhang length measurement; comparison of IDC, IHD, and non-failing heart samples\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — preprint, observational/correlative biochemical measurements in human tissue without functional manipulation of TERF2\",\n      \"pmids\": [\"bio_10.1101_2025.08.12.669993\"],\n      \"is_preprint\": true\n    }\n  ],\n  \"current_model\": \"TERF2 (TRF2) is a telomeric double-strand DNA-binding protein whose DNA-binding domain is required for telomeric localization; it protects chromosome ends by suppressing ATM-dependent DNA damage signaling (acting via ATM and TP53 in neural cells), forms a complex with XPF to participate in non-telomeric DNA damage responses, interacts directly with HMGB1 to restrict its cytoplasmic translocation and thereby suppress autophagy, and in ALT cancer cells is stabilized at telomeres by TOP3A activity.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"TERF2 (TRF2) is a telomeric double-strand DNA-binding protein that protects chromosome ends and governs the DNA damage response, with its DNA-binding domain required for proper targeting to telomeres [#3]. At chromosome ends, loss of TERF2 triggers telomere dysfunction that activates an ATM- and TP53-dependent, ATR-independent apoptotic program; in neural progenitors this drives catastrophic cell loss, and unrepaired double-strand breaks processed by NHEJ (Lig4) underlie the multinucleated cells that arise when p53 is absent [#1]. Beyond telomeres, TERF2 forms a complex with the nucleotide excision repair endonuclease XPF that acts at non-telomeric damage sites upstream of ATM signaling, such that TERF2 overexpression sensitizes cells to UV and crosslinking agents in an XPF-dependent manner [#2]. TERF2 also exerts a non-telomeric regulatory role by binding directly to HMGB1 and restricting its cytoplasmic translocation; this interaction suppresses autophagy, as TERF2 silencing drives HMGB1 to the cytosol and stimulates autophagy while a binding-deficient mutant fails to suppress it [#0].\",\n  \"teleology\": [\n    {\n      \"year\": 2005,\n      \"claim\": \"Established that TERF2's telomeric localization is an intrinsic property of its DNA-binding domain, defining how the protein finds chromosome ends.\",\n      \"evidence\": \"TRF2-GFP fusion imaging and DNA-binding-domain deletion mutants in muntjac fibroblast cell lines\",\n      \"pmids\": [\"15878333\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Single lab and single ortholog cell line\",\n        \"Does not address what stabilizes TERF2 once bound or which cofactors are required\",\n        \"No structural detail of the DNA-binding interface\"\n      ]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Extended TERF2 function beyond telomeres by showing it partners with XPF to act at non-telomeric DNA damage sites prior to ATM signaling.\",\n      \"evidence\": \"TERF2 overexpression in XPF-deficient vs. XPF-proficient cells with UV/crosslinker sensitivity assays, synthesized in a review commentary\",\n      \"pmids\": [\"16762604\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Evidence summarized from original papers in a review context\",\n        \"Molecular nature of the TERF2-XPF complex and its substrate are not defined\",\n        \"Physiological relevance of the gain-of-function hypersensitivity is unclear\"\n      ]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Defined the genetic pathway of TERF2 loss in vivo, showing telomere dysfunction signals through ATM and TP53 (not ATR) to drive apoptosis and that NHEJ underlies aberrant cell formation.\",\n      \"evidence\": \"Conditional Terf2 knockout in mouse neural progenitors crossed with Atm, Atr, Trp53, and Lig4 knockouts, with developmental histology\",\n      \"pmids\": [\"28620865\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Restricted to the neural progenitor context\",\n        \"Does not resolve the molecular step linking telomere deprotection to ATM activation\",\n        \"Role of TERF2 partners in this signaling is not addressed\"\n      ]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Uncovered a non-telomeric role for TERF2 as a direct binding partner that sequesters HMGB1 in the nucleus to restrain autophagy.\",\n      \"evidence\": \"Co-IP, PLA, wild-type vs. binding-deficient TERF2 mutant rescue, HMGB1 knockdown/inhibitor epistasis, and GFP-LC3 autophagy reporter\",\n      \"pmids\": [\"36310382\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether HMGB1 binding occurs at telomeres or elsewhere is not localized\",\n        \"How TERF2's telomeric and autophagy-regulatory functions are coordinated is unknown\",\n        \"In vivo relevance of the autophagy axis is not established\"\n      ]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Positioned TERF2 within regulatory and oncogenic networks: as a target of miR-29b-1-5p in myocardial injury and, when fused to PDGFRB, as a driver of kinase-dependent proliferation.\",\n      \"evidence\": \"Dual luciferase 3'UTR validation with TERF2-knockdown rescue in cardiomyocytes; Ba/F3 expression of TERF2::PDGFRB fusion with STAT5 signaling readouts and imatinib sensitivity\",\n      \"pmids\": [\"38414350\", \"38323741\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"miR-29b axis is correlative for endogenous TERF2 protein function\",\n        \"The fusion's oncogenic activity reflects PDGFRB kinase rather than native TERF2 function\",\n        \"Single-lab studies in defined model systems\"\n      ]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Began to address how TERF2 is retained at telomeres in ALT cancer cells, implicating TOP3A activity in its stabilization.\",\n      \"evidence\": \"Telomere enrichment/ChIP comparing ALT vs. telomerase-positive cells with TOP3A depletion and DPC induction (preprint)\",\n      \"pmids\": [\"bio_10.1101_2024.11.18.624152\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"Preprint; lacks full mechanistic reconstitution\",\n        \"Mechanism by which TOP3A stabilizes TERF2 is undefined\",\n        \"Generalizability beyond the ALT cell context is untested\"\n      ]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Correlated TERF2 telomere de-protection with disease, linking reduced telomeric TERF2 to telomere damage signaling in failing human hearts.\",\n      \"evidence\": \"Telomere ChIP, γH2AX/TIF assays, and overhang measurements in failing vs. non-failing human left ventricular tissue (preprint)\",\n      \"pmids\": [\"bio_10.1101_2025.08.12.669993\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"Preprint; observational and correlative without TERF2 manipulation\",\n        \"Causality between TERF2 loss and heart failure is not established\",\n        \"Mechanism of TERF2 loss from telomeres in failing hearts is unknown\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How TERF2 coordinates its telomere-protective DNA-binding role with its non-telomeric XPF and HMGB1 functions, and what governs its stability at telomeres in different cellular contexts, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"No structural model integrating DNA binding with partner interactions\",\n        \"Mechanism of TERF2 stabilization/loss at telomeres across cell types undefined\",\n        \"Direct causal link between TERF2 de-protection and human disease not demonstrated\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [3]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0000228\", \"supporting_discovery_ids\": [3, 1]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [2, 1]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"HMGB1\", \"XPF\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"tie","faith_supported":4,"faith_total":4,"faith_pct":100.0}}